Adalimumab (HUMIRA) Halts Radiographic Progression and Reduces Disease Activity in Patients with a Poor Initial Response to Methotrexate

被引：0
|
作者：
Smolen, Josef S. [1 ,2 ]
van Vollenhoven, Ronald F. [3 ]
Wolfe, Benjamin A. [4 ]
Chen, Su [4 ]
Suboticki, Jessica L. [4 ]
Kavanaugh, Arthur [5 ]
机构：
[1] Med Univ Vienna, Dept Med, Div Rheumatol, Vienna, Austria
[2] Hietzing Hosp, Vienna, Austria
[3] Amsterdam Rheumatol & Immunol Ctr ARC, Amsterdam, Netherlands
[4] AbbVie Inc, N Chicago, IL USA
[5] Univ Calif San Diego, Div Rheumatol Allergy & Immunol, La Jolla, CA 92093 USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
593
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Inhibition of radiographic progression in RA patients with moderate disease activity treated with adalimumab and methotrexate
    Keystone, E. C.
    Furst, D. E.
    Kavanaugh, A. F.
    Perez, J.
    Segurado, Oscar
    RHEUMATOLOGY, 2008, 47 : II44 - II44
  • [2] Subgroup analysis of radiographic progression in RA patients with moderate disease treated with adalimumab (Humira®)
    Keystone, EC
    Furst, DE
    Kavanaugh, AF
    Spencer-Green, GT
    Szczerbak, NA
    Mydler, TT
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 267 - 267
  • [3] Inhibition of radiographic disease progression in patients with long-standing rheumatoid arthritis following 3 years of treatment with adalimumab (HUMIRA®) plus methotrexate
    Keystone, EC
    Kavanaugh, AF
    Sharp, JT
    Spencer-Green, GT
    Perez, JL
    Sasso, EH
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 419 - 419
  • [4] Combination etanercept and methotrexate halts radiographic damage in patients with moderate RA activity on methotrexate
    van der Heijde, D.
    Gomez-Reino, J. J.
    Tuomiranta, T.
    Kekow, J.
    Robertson, D.
    Pedersen, R.
    Freundlich, B.
    Chang, D. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 191 - 191
  • [5] The addition of adalimumab to methotrexate reduces rheumatoid arthritis activity in patients with longstanding disease
    Matucci-Cerinic, M
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2004, 22 (01) : 34 - 35
  • [6] The relationship of radiographic progression to clinical response in patients with early RA treated with adalimumab (HUMIRA®) plus MTX or MTX alone.
    Genovese, MC
    Kavanaugh, AF
    Cohen, SB
    Emery, P
    Sasso, EH
    Spencer-Green, GT
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S451 - S451
  • [7] ADALIMUMAB (HUMIRA®) INHIBITS RADIOGRAPHIC PROGRESSION IN RHEUMATOID ARTHRITIS (RA) PATIENTS WITH LONG-STANDING DISEASE: DATA AT TWO YEARS
    Keystone, E.
    Kavanaugh, A.
    Sharp, J.
    Spencer-Green, G.
    Segurado, O. G.
    RHEUMATOLOGY, 2004, 43 : 10 - 10
  • [8] Methotrexate and radiographic disease progression in patients with rheumatoid arthritis
    Kremer, JM
    JOURNAL OF RHEUMATOLOGY, 1999, 26 (02) : 241 - 243
  • [9] Assessment of disease activity and treatment response to adalimumab (HUMIRA®) in RA with the simplified disease activity index (SDAI).
    Smolen, JS
    Breedveld, FC
    Schiff, MH
    Kalden, JR
    Emery, P
    Segurado, OG
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S190 - S191
  • [10] Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate
    Smolen, Josef S.
    van Vollenhoven, Ronald F.
    Florentinus, Stefan
    Chen, Su
    Suboticki, Jessica L.
    Kavanaugh, Arthur
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (11) : 1566 - 1572
12345